Should you invest in Axos Bank?
Axos Financial is highly exposed to America’s commercial-property slump


The past four years have radically changed the landscape of the US property market. The residential market has surged, with the average house price now nearly 50% higher than in January 2020. However, it has been a very different story for the commercial property market due to remote working. Despite the best efforts of some prominent technology companies, all the evidence suggests that the return to the office in the US has stalled. Office vacancy rates have continued to increase as firms decide to save money by not renewing their leases, or selling their offices.
Around 15% of office space in the United States is vacant (double the pre-Covid figure), but the rates are even higher in the major cities, such as Los Angeles and Chicago. In San Francisco, more than 20% of office space is vacant. This is not only bad news for property companies, but also for banks such as Axos Financial (NYSE: AX).
As short-seller Hindenburg Research has pointed out, instead of cutting its exposure to the flatlining commercial market, Axos has significantly increased lending to the commercial sector, nearly doubling it over the past three years. Commercial property (counting apartment blocks, which are also doing badly) now accounts for slightly more than half the bank’s loan book.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
How investors feel about Axos Bank
Although headquartered in California, Axos has made a particularly strong push into New York’s commercial property sector. While the city’s vacancy rates are roughly the same as those in the US as a whole, there has been a surge in repossessions in recent months, and experts predict worse to come. The rate at which commercial properties are being foreclosed is one of the highest in the US, and rising. Even more worryingly, Axos’s loan book is especially concentrated on a relatively small number of individual projects, with one developer comprising nearly 5% of its total loan book.
There are also anecdotal indications that, in a bid to expand, Axos has lowered its lending standards, taking on commercial loans that other lenders in the area are unwilling to back, and making high-risk loans to firms in other sectors, such as cryptocurrencies. Despite these risks, investors continue to be extremely bullish about Axos. Although most comparable midsized US banks typically trade at, or on, a small premium to the value of their net tangible assets, Axos is valued at a much larger 51% premium.
The market has ignored these problems, even though Axos is one of the most shorted small regional banks. The stock nearly doubled from $33 in November to a high of $61 last month. However, it has now fallen back by around 15%, and is trading below its 50-day moving average. I, therefore, suggest that you short Axos at the current price of $53.75 at £40 per $1. In this case, I’d put the stop loss at $77.75. This should give you a total downside risk of £960.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
Was Margaret Thatcher great for Britain?
The 'Iron Lady’ would be celebrating her 100th birthday this month. Margaret Thatcher rose to power in 1979 as the first ever female prime minister and was one of the most controversial leaders in history, but how did her policies shape today’s finances?
-
Pierre-Édouard Stérin wants to make France great again
Conservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growth
Pinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'
Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
A tale of two Reits – why performance matters for valuation
AEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?
-
'It’s time to buy British equities'
Opinion There is no better place to start investing in UK equities than with two of MoneyWeek’s favourite investment trusts, says Max King
-
To hedge or not to hedge, that is the question
The mechanics of hedging are very logical, but deciding when to add a hedge is rarely a simple decision